Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote in favor of the Top Vegetable for Senior - 2Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- 3Israel scales back use of top missile interceptors as Iran barrages persist
- 4Down to earth Manual for A Modest Hyundai Ioniq Electric for Seniors
- 5Embrace the Outside: Exercises and Entertainment
- Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- Truly amazing Palaces: Which Is Your Number one?
- 6 Objections for an Ocean side Wedding
- Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- New law puts familiar drinks, creams and gummies in legal limbo
- How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- Vote In favor of Your #1 Compelling Female Producer
- Flu season is underway. What are common symptoms to watch for?
